Cole J C, Lin P, Rupnow M F T
QualityMetric, Lincoln, RI 02865-4207, USA.
Cephalalgia. 2009 Nov;29(11):1180-7. doi: 10.1111/j.1468-2982.2009.01852.x.
To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.
提出偏头痛特异性生活质量问卷2.1版(MSQ v2.1)的最小重要差异(MID)。据我们所知(截至目前),在任何人群中均不存在已发表的MSQ v2.1的MID值。对来自两项托吡酯预防偏头痛关键临床试验(n = 916)以及QualityMetric全国头痛调查(n = 1016)的数据进行了分析。分析包括基于分布和锚定的MID技术以及组水平和个体水平的MID值。组水平基于锚定的MID值范围为3.2[角色限制领域(RR)]至7.5[情绪功能领域(EF)],设定了适当MID的最低水平(这也有助于功效分析)。个体水平基于分布的MID值在两个大型数据库中得出了高度相似的估计值:RR的MID中位数为8.5,角色预防(RP)为9.2,EF为12.0。最后,个体水平基于锚定的MID值范围为5.0(RR和RP领域)至10.6(EF)。出于计算未来研究功效的组水平目的,建议RR、RP和EF的MID分别为3.2、4.6和7.5。对于使用应答者分析来分析每位患者变化的临床试验疗效的组内分析,RR需要5分。对于RP和EF,建议使用范围:RP为5.0至7.9,EF为8.0至10.6。后两个领域的MID往往存在更多误差,因此应使用范围两端的敏感性分析来确认应答者分析中的显著差异。